IL33 and rheumatoid arthritis: Aside from this, the authors demonstrated that serum IL-33 levels decreased significantly after 24 weeks of tocilizumab therapy (p < 0.001), thus strengthening the concept that IL-33 could be used as a marker to monitor therapy response in RA.